To evaluate the biological effects of MAD2L1 and BUB1 on breast cancer, we designed two RNA interference (RNAi) assays to knockdown the expression of MAD2L1 or BUB1. The experiments were performed in two triple-negative breast cancer cell lines MDA-MB-231 and MDA-MB-468, which had high expression of endogenous MAD2L1 and BUB1. Cell growth, invasion and migration were evaluated in our in vitro experiments. The gene discussed is MAD2L1; the disease is triple-negative breast carcinoma.